<!DOCTYPE html><html lang="en" class="__variable_6d343d __variable_49a339"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/26d4368bf94c0ec4-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/36966cca54120369-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo.svg" fetchPriority="high"/><link rel="stylesheet" href="/_next/static/css/5bd3404007bffd2a.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-04cc3a393714a88b.js"/><script src="/_next/static/chunks/fd9d1056-4b87d5bb1aa946b3.js" async=""></script><script src="/_next/static/chunks/23-7a13f39f0e990758.js" async=""></script><script src="/_next/static/chunks/main-app-9c6ab80fd9a4d8e3.js" async=""></script><script src="/_next/static/chunks/231-9e11bdfe3b664aec.js" async=""></script><script src="/_next/static/chunks/app/sectors/%5Bsector%5D/page-cded06e59a9455a8.js" async=""></script><script src="/_next/static/chunks/896-78f6f35c40d7ae60.js" async=""></script><script src="/_next/static/chunks/391-7f9e7fb294aae160.js" async=""></script><script src="/_next/static/chunks/app/layout-6784eb5ba9ddff8d.js" async=""></script><link rel="icon" href="/logo.svg" type="image/svg+xml"/><title>health care sector stocks on the ASX | trends &amp; top performers | ASX Desk</title><meta name="description" content="Explore ASX health care stocks, sector trends, and leading performers with AI-generated insights."/><link rel="canonical" href="https://asxdesk.com/sectors/health%20care/"/><meta property="og:title" content="health care sector stocks on the ASX | trends &amp; top performers"/><meta property="og:description" content="Explore ASX health care stocks, sector trends, and leading performers with AI-generated insights."/><meta property="og:url" content="https://asxdesk.com/sectors/health%20care/"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="ASX Desk"/><meta name="twitter:description" content="Australia&#x27;s AI-powered ASX stock research platform delivering instant analysis, sector insights, and SEO-optimized company profiles."/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js" noModule=""></script></head><body class="min-h-screen bg-ink-900 text-slate-100"><div class="min-h-screen"><header class="sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur"><div class="mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8"><a class="flex items-center gap-3" href="/"><img alt="ASX Desk" fetchPriority="high" width="140" height="40" decoding="async" data-nimg="1" class="h-10 w-auto" style="color:transparent" src="/logo.svg"/><span class="hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline">Research Terminal</span></a><nav class="hidden items-center gap-6 text-sm text-slate-300 md:flex"><a class="transition hover:text-white" href="/">Home</a><a class="transition hover:text-white" href="/screener/">Screener</a><a class="transition hover:text-white" href="/sectors/">Sectors</a><a class="transition hover:text-white" href="/news/">News</a><a class="transition hover:text-white" href="/ipos/">IPOs</a><a class="transition hover:text-white" href="/compare/">Compare</a><a class="transition hover:text-white" href="/about/">About</a></nav><div class="hidden items-center gap-3 md:flex"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search ticker…" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div><button class="rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20">Premium Research</button><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400">Open Account</button></div></div><div class="flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden"><div class="flex-1"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search ticker…" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div></div><a class="shrink-0 text-xs text-blue-300" href="/screener/">Screener</a></div></header><main class="mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8"><div class="space-y-10"><section class="rounded-2xl border border-white/10 bg-ink-900/80 p-6"><p class="text-xs uppercase tracking-[0.3em] text-blue-300">Sector</p><h1 class="mt-2 font-display text-3xl font-semibold">health care<!-- --> Stocks</h1><p class="mt-4 text-sm text-slate-300">Deep-dive coverage on ASX <!-- -->health care<!-- --> leaders, thematic trends, and relative performance signals. Our AI engine tracks earnings momentum, capital allocation, and sector rotation.</p><div class="mt-5 flex flex-wrap gap-3 text-xs text-slate-400"><span class="rounded-full border border-white/10 px-3 py-1">166<!-- --> stocks tracked</span><span class="rounded-full border border-white/10 px-3 py-1">Updated daily</span><span class="rounded-full border border-white/10 px-3 py-1">AI sector heatmaps</span></div></section><section class="grid gap-4 sm:grid-cols-2 lg:grid-cols-4"><div class="rounded-2xl border border-white/10 bg-ink-900/80 p-5"><p class="text-xs uppercase tracking-wide text-slate-500">Total Stocks</p><p class="mt-1 font-display text-2xl font-semibold text-white">166</p></div><div class="rounded-2xl border border-white/10 bg-ink-900/80 p-5"><p class="text-xs uppercase tracking-wide text-slate-500">Avg 1Y Performance</p><p class="mt-1 font-display text-2xl font-semibold text-emerald-400">+<!-- -->35.0<!-- -->%</p></div><div class="rounded-2xl border border-white/10 bg-ink-900/80 p-5"><p class="text-xs uppercase tracking-wide text-slate-500">Best Performer</p><p class="mt-1 font-display text-2xl font-semibold text-emerald-400">4DX</p><p class="text-xs text-emerald-400/80">+<!-- -->1325.9<!-- -->%</p></div><div class="rounded-2xl border border-white/10 bg-ink-900/80 p-5"><p class="text-xs uppercase tracking-wide text-slate-500">Worst Performer</p><p class="mt-1 font-display text-2xl font-semibold text-red-400">ENL</p><p class="text-xs text-red-400/80">-87.0<!-- -->%</p></div></section><section class="grid gap-6 lg:grid-cols-2"><div class="rounded-2xl border border-white/10 bg-ink-900/80 p-6"><h2 class="font-display text-lg font-semibold">Top Performers</h2><div class="mt-4 space-y-3"><div class="flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4"><div><p class="font-semibold text-white">4DX</p><p class="text-xs text-slate-400">4Dmedical Limited</p></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.85</p><span class="text-sm font-semibold text-emerald-400">+<!-- -->1325.9<!-- -->%</span></div></div><div class="flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4"><div><p class="font-semibold text-white">LDX</p><p class="text-xs text-slate-400">Lumos Diagnostics Holdings Limited</p></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.26</p><span class="text-sm font-semibold text-emerald-400">+<!-- -->983.3<!-- -->%</span></div></div><div class="flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4"><div><p class="font-semibold text-white">NYR</p><p class="text-xs text-slate-400">Nyrada Inc.</p></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.80</p><span class="text-sm font-semibold text-emerald-400">+<!-- -->644.2<!-- -->%</span></div></div></div></div><div class="rounded-2xl border border-white/10 bg-ink-900/80 p-6"><h2 class="font-display text-lg font-semibold">Worst Performers</h2><div class="mt-4 space-y-3"><div class="flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4"><div><p class="font-semibold text-white">ENL</p><p class="text-xs text-slate-400">Enlitic Inc.</p></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><span class="text-sm font-semibold text-red-400">-87.0<!-- -->%</span></div></div><div class="flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4"><div><p class="font-semibold text-white">UBI</p><p class="text-xs text-slate-400">Universal Biosensors Inc.</p></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><span class="text-sm font-semibold text-red-400">-79.7<!-- -->%</span></div></div><div class="flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4"><div><p class="font-semibold text-white">BOT</p><p class="text-xs text-slate-400">Botanix Pharmaceuticals Ltd</p></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.11</p><span class="text-sm font-semibold text-red-400">-75.8<!-- -->%</span></div></div></div></div></section><section class="space-y-6"><div class="flex items-end justify-between"><h2 class="font-display text-2xl font-semibold">All <!-- -->health care<!-- --> Coverage</h2><p class="text-sm text-slate-400">Showing <!-- -->20<!-- --> of <!-- -->166<!-- --> stocks</p></div><div class="grid gap-6 md:grid-cols-2"><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/4DX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">4DX<span class="ml-2 text-sm text-slate-400">4Dmedical Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.85</p><p class="text-xs font-semibold text-emerald-400">1325.9<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">4Dmedical Limited specializes in developing and commercializing state-of-the-art respiratory imaging technology, notably its XV Lung Ventilation Analysis Software (XV LVAS). This non-invasive technology provides quantitative and visual assessments of regional lung function, aiming to improve the diagnosis and management of various respiratory conditions. The company primarily operates in Australia and is aggressively expanding its presence in the large US healthcare market.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$2.0B</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/LDX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">LDX<span class="ml-2 text-sm text-slate-400">Lumos Diagnostics Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.26</p><p class="text-xs font-semibold text-emerald-400">983.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Lumos Diagnostics Holdings Limited (ASX: LDX) is an Australian-based company developing and commercialising rapid, point-of-care (POC) diagnostic tests for infectious diseases. Their flagship product, FebriDx, aims to differentiate bacterial from viral infections within minutes, assisting clinicians in reducing unnecessary antibiotic prescriptions. Lumos operates globally with R&amp;D and manufacturing facilities in the US, targeting healthcare markets across North America, Europe, and Australia.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$218M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NYR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NYR<span class="ml-2 text-sm text-slate-400">Nyrada Inc.</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.80</p><p class="text-xs font-semibold text-emerald-400">644.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Nyrada Inc. is an Australian-based biotechnology company focused on the development of novel neuroprotectants and cardiovascular therapeutics. The company&#x27;s lead programs target significant medical needs such as traumatic brain injury, stroke, and certain cardiovascular diseases, with drug candidates in pre-clinical and early clinical development phases. Nyrada operates primarily in the research and development sector, aiming to develop first-in-class treatments.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$198M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/DVL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">DVL<span class="ml-2 text-sm text-slate-400">Dorsavi Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">483.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Dorsavi Ltd (ASX: DVL) is an Australian-based company that develops wearable sensor technology and software solutions for analyzing human movement. Their proprietary technology provides objective data for injury prevention, performance enhancement, and clinical rehabilitation across elite sports, occupational health, and healthcare sectors, operating globally.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$39M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/SPL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">SPL<span class="ml-2 text-sm text-slate-400">Starpharma Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.49</p><p class="text-xs font-semibold text-emerald-400">421.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Starpharma Holdings Limited (SPL) is an Australian biotech company specializing in pharmaceuticals and life sciences. Headquartered in Melbourne, SPL operates globally, focusing on drug delivery technologies, with its lead product being Dendrimers, particularly the proprietary DuraGel technology for enhancing drug efficacy and safety. Key products include clinical-stage oncology and infectious disease treatments.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$174M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AYA/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AYA<span class="ml-2 text-sm text-slate-400">Artrya Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->3.56</p><p class="text-xs font-semibold text-emerald-400">374.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Artrya Limited is an Australian medical technology company that develops and commercializes AI-powered software for the diagnosis of coronary artery disease. Its flagship product, Salix, analyzes cardiac CT scans to identify stenosis and vulnerable plaque, aiming to improve diagnostic accuracy and prevent heart attacks. The company targets cardiologists, radiologists, and hospitals globally, with key regulatory approvals in Australia, Europe, and the USA.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$550M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AI/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AI<span class="ml-2 text-sm text-slate-400">Algorae Pharmaceuticals Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-emerald-400">320.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere&#x27;s disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$37M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/NSB/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">NSB<span class="ml-2 text-sm text-slate-400">Neuroscientific Biopharmaceuticals Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.13</p><p class="text-xs font-semibold text-emerald-400">251.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Neuroscientific Biopharmaceuticals Ltd (NSB) is an Australian clinical-stage pharmaceutical company focused on developing novel peptide-based drugs for neurological and neurodegenerative disorders. Their lead drug candidate, EmtinB, targets conditions such as Alzheimer&#x27;s disease, Multiple Sclerosis, and glaucoma, aiming to address significant unmet medical needs. The company is advancing its proprietary therapeutic compounds through various stages of preclinical and clinical development.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$43M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ICR/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ICR<span class="ml-2 text-sm text-slate-400">Intelicare Holdings Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.02</p><p class="text-xs font-semibold text-emerald-400">233.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Intelicare Holdings Limited (ASX: ICR) is an Australian technology company specializing in AI-powered assistive living solutions for the aged care and disability support sectors. Its flagship InteliCare platform uses sensors and artificial intelligence to monitor the well-being of individuals remotely, providing insights to carers and family members without invasive surveillance. The company primarily operates within the Australian market, aiming to improve independent living outcomes.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$14M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RHY/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RHY<span class="ml-2 text-sm text-slate-400">Rhythm Biosciences Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.24</p><p class="text-xs font-semibold text-emerald-400">206.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Rhythm Biosciences Limited (ASX: RHY) is an Australian medical diagnostics company focused on developing and commercialising its lead product, ColoSTAT, a simple blood test for the early detection of colorectal cancer. The company aims to provide a more accessible and non-invasive screening solution globally, primarily targeting markets in Australia, Europe, and the USA.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$74M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/BB1/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">BB1<span class="ml-2 text-sm text-slate-400">Blinklab Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.03</p><p class="text-xs font-semibold text-emerald-400">167.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Blinklab Limited (ASX: BB1) is a Australian health tech company, operating in the health care equipment and services sector. Specific to the Australian market, it develops innovative, non-invasive diagnostic devices for early detection of ophthalmological conditions, leveraging AI-driven analysis. Key product is &#x27;EyeSightAI&#x27;, targeting the Australian healthcare system and private clinics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$128M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/ILA/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">ILA<span class="ml-2 text-sm text-slate-400">Island Pharmaceuticals Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.41</p><p class="text-xs font-semibold text-emerald-400">148.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Island Pharmaceuticals Limited (ASX: ILA) is an early-stage Australian biotechnology company focused on the research, development, and commercialization of innovative therapeutic solutions in the pharmaceuticals and biotechnology sector. Primarily operating in Australia, with potential for global clinical trials, ILA is currently pre-revenue, concentrating on advancing its lead compound through clinical phases, targeting specific unmet medical needs. Key products/services include its proprietary drug candidate for [undisclosed target disease/condition, assuming specificity not publicly available, thus a placeholder].</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$112M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AT1/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AT1<span class="ml-2 text-sm text-slate-400">Atomo Diagnostics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">141.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Atomo Diagnostics Limited (ASX: AT1) is an Australian medical device company specialising in the design, manufacture, and commercialisation of user-friendly rapid diagnostic test (RDT) devices. Its patented AtomoRapid platform simplifies blood-based point-of-care and self-test applications, aiming to improve testing accuracy and accessibility for various infectious diseases globally.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$33M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/RAC/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">RAC<span class="ml-2 text-sm text-slate-400">Racura Oncology Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->2.40</p><p class="text-xs font-semibold text-emerald-400">125.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Ratura Oncology Ltd (ASX: RAC) is an Australian-listed biotechnology company focused on the discovery, development, and commercialization of novel therapeutic candidates for the treatment of various cancers. Operating primarily in the preclinical and clinical trial phases, the company aims to address unmet medical needs within oncology by advancing its pipeline of drug candidates.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$445M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AHX/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AHX<span class="ml-2 text-sm text-slate-400">Apiam Animal Health Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.88</p><p class="text-xs font-semibold text-emerald-400">124.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Apiam Animal Health Limited is a leading provider of veterinary services, operating a network of clinics predominantly across regional and rural Australia. The company offers a comprehensive range of veterinary care for companion animals, equine, and livestock, along with related products and services.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$-1</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/TRI/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">TRI<span class="ml-2 text-sm text-slate-400">Trivarx Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-emerald-400">122.2<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Trivarx Ltd is an Australian medical technology company developing its proprietary &#x27;Cardi-Dx&#x27; point-of-care diagnostic platform. The device is designed for the rapid detection of key cardiac biomarkers from a single drop of blood, targeting the early and accurate diagnosis of acute cardiac events in emergency departments and clinics. The company is currently advancing the Cardi-Dx system through clinical trials and regulatory approval pathways in Australia and Europe.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$29M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/HMD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">HMD<span class="ml-2 text-sm text-slate-400">Heramed Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.04</p><p class="text-xs font-semibold text-emerald-400">121.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Heramed Limited (ASX: HMD) is an Australian-Israeli digital health company focused on remote pregnancy monitoring solutions. Its flagship product, HeraBEAT, is a medical-grade, CE-marked, and TGA-approved device enabling expectant mothers to monitor vital signs and fetal heart rate from home. The company operates globally by partnering with healthcare providers and health systems to integrate its technology into patient care pathways.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$45M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CYP/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CYP<span class="ml-2 text-sm text-slate-400">Cynata Therapeutics Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.39</p><p class="text-xs font-semibold text-emerald-400">110.8<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Cynata Therapeutics Limited (ASX: CYP) is an Australian biotechnology company focused on developing innovative cellular therapies for serious diseases using its proprietary Cell Control Technology. Operating primarily in the Australian market with research collaborations globally, its key product in development is rCTRM, a mesenchymal stromal cell therapy for acute respiratory distress syndrome (ARDS) and other inflammatory conditions.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$91M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CC5/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CC5<span class="ml-2 text-sm text-slate-400">Clever Culture Systems Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.03</p><p class="text-xs font-semibold text-emerald-400">107.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Clever Culture Systems Limited (CC5) is an Australian healthcare equipment and services company developing innovative cell culture solutions for the biotechnology and pharmaceutical industries. Operating primarily in Australia, with potential expansion to APAC regions, its key product is the Clever Culture SystemTM, designed to enhance cell growth and efficiency in research and production settings.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$65M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/AVE/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">AVE<span class="ml-2 text-sm text-slate-400">Avecho Biotechnology Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-emerald-400">100.0<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Avecho Biotechnology Limited (ASX: AVE) operates in Australia, specializing in the development of innovative therapeutic products for unmet medical needs. Focused on proprietary formulations and delivery technologies for existing drugs, improving efficacy and patient outcomes. Key product pipeline: Novel formulations for pain management and neurology.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$35M</span><span class="text-blue-300">View analysis</span></div></a></div><p class="text-center text-sm text-slate-500">+<!-- -->146<!-- --> more <!-- -->health care<!-- --> stocks available. Use the<!-- --> <a href="/screener" class="text-blue-400 hover:underline">Screener</a> <!-- -->to filter and explore the full list.</p></section></div></main><footer class="border-t border-white/10 bg-ink-800/60"><div class="mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8"><div><h3 class="font-display text-lg font-semibold">ASX Desk</h3><p class="mt-3 text-sm text-slate-400">Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.</p><div class="mt-4 flex gap-3"><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button><button class="rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300">Download Media Kit</button></div></div><div class="grid grid-cols-2 gap-6 text-sm text-slate-400"><div><h4 class="mb-2 font-semibold text-slate-200">Platform</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/screener/">Screener</a></li><li><a class="hover:text-white" href="/news/">News &amp; Commentary</a></li><li><a class="hover:text-white" href="/about/">About</a></li></ul></div><div><h4 class="mb-2 font-semibold text-slate-200">Sectors</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/sectors/materials/">Materials</a></li><li><a class="hover:text-white" href="/sectors/financials/">Financials</a></li><li><a class="hover:text-white" href="/sectors/health care/">Health Care</a></li><li><a class="hover:text-white" href="/sectors/information technology/">Information Tech</a></li><li><a class="hover:text-white" href="/sectors/energy/">Energy</a></li></ul></div></div><div class="glass-card rounded-2xl p-6"><h4 class="font-semibold">Weekly Alpha Briefing</h4><p class="mt-2 text-sm text-slate-400">Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.</p><div class="mt-4 flex flex-col gap-3 sm:flex-row"><input type="email" placeholder="you@example.com" class="w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"/><button class="rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white">Subscribe</button></div><p class="mt-3 text-xs text-slate-500">By subscribing you agree to receive marketing updates. Unsubscribe anytime.</p></div></div><div class="border-t border-white/10 py-6 text-center text-xs text-slate-500"><p>General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.</p></div></footer></div><script src="/_next/static/chunks/webpack-04cc3a393714a88b.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/26d4368bf94c0ec4-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/media/36966cca54120369-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n3:HL[\"/_next/static/css/5bd3404007bffd2a.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\n6:I[231,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"362\",\"static/chunks/app/sectors/%5Bsector%5D/page-cded06e59a9455a8.js\"],\"\"]\n7:I[9275,[],\"\"]\n9:I[1343,[],\"\"]\na:I[8173,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"391\",\"static/chunks/391-7f9e7fb294aae160.js\",\"185\",\"static/chunks/app/layout-6784eb5ba9ddff8d.js\"],\"Image\"]\nb:I[4019,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"391\",\"static/chunks/391-7f9e7fb294aae160.js\",\"185\",\"static/chunks/app/layout-6784eb5ba9ddff8d.js\"],\"default\"]\nd:I[6130,[],\"\"]\n8:[\"sector\",\"health%20care\",\"d\"]\ne:[]\n"])</script><script>self.__next_f.push([1,"0:[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/5bd3404007bffd2a.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"$L4\",null,{\"buildId\":\"ujAyz4UDjjKKgpu0I6XQ2\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/sectors/health%20care/\",\"initialTree\":[\"\",{\"children\":[\"sectors\",{\"children\":[[\"sector\",\"health%20care\",\"d\"],{\"children\":[\"__PAGE__?{\\\"sector\\\":\\\"health care\\\"}\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"sectors\",{\"children\":[[\"sector\",\"health%20care\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"div\",null,{\"className\":\"space-y-10\",\"children\":[[\"$\",\"section\",null,{\"className\":\"rounded-2xl border border-white/10 bg-ink-900/80 p-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"Sector\"}],[\"$\",\"h1\",null,{\"className\":\"mt-2 font-display text-3xl font-semibold\",\"children\":[\"health care\",\" Stocks\"]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-300\",\"children\":[\"Deep-dive coverage on ASX \",\"health care\",\" leaders, thematic trends, and relative performance signals. Our AI engine tracks earnings momentum, capital allocation, and sector rotation.\"]}],[\"$\",\"div\",null,{\"className\":\"mt-5 flex flex-wrap gap-3 text-xs text-slate-400\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":[166,\" stocks tracked\"]}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Updated daily\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"AI sector heatmaps\"}]]}]]}],[\"$\",\"section\",null,{\"className\":\"grid gap-4 sm:grid-cols-2 lg:grid-cols-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"rounded-2xl border border-white/10 bg-ink-900/80 p-5\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-wide text-slate-500\",\"children\":\"Total Stocks\"}],[\"$\",\"p\",null,{\"className\":\"mt-1 font-display text-2xl font-semibold text-white\",\"children\":166}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-2xl border border-white/10 bg-ink-900/80 p-5\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-wide text-slate-500\",\"children\":\"Avg 1Y Performance\"}],[\"$\",\"p\",null,{\"className\":\"mt-1 font-display text-2xl font-semibold text-emerald-400\",\"children\":[\"+\",\"35.0\",\"%\"]}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-2xl border border-white/10 bg-ink-900/80 p-5\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-wide text-slate-500\",\"children\":\"Best Performer\"}],[\"$\",\"p\",null,{\"className\":\"mt-1 font-display text-2xl font-semibold text-emerald-400\",\"children\":\"4DX\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-emerald-400/80\",\"children\":[\"+\",\"1325.9\",\"%\"]}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-2xl border border-white/10 bg-ink-900/80 p-5\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-wide text-slate-500\",\"children\":\"Worst Performer\"}],[\"$\",\"p\",null,{\"className\":\"mt-1 font-display text-2xl font-semibold text-red-400\",\"children\":\"ENL\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-red-400/80\",\"children\":[\"\",\"-87.0\",\"%\"]}]]}]]}],[\"$\",\"section\",null,{\"className\":\"grid gap-6 lg:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"rounded-2xl border border-white/10 bg-ink-900/80 p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Top Performers\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3\",\"children\":[[\"$\",\"div\",\"4DX\",{\"className\":\"flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"4DX\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"4Dmedical Limited\"}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.85\"]}],[\"$\",\"span\",null,{\"className\":\"text-sm font-semibold text-emerald-400\",\"children\":[\"+\",\"1325.9\",\"%\"]}]]}]]}],[\"$\",\"div\",\"LDX\",{\"className\":\"flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"LDX\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Lumos Diagnostics Holdings Limited\"}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.26\"]}],[\"$\",\"span\",null,{\"className\":\"text-sm font-semibold text-emerald-400\",\"children\":[\"+\",\"983.3\",\"%\"]}]]}]]}],[\"$\",\"div\",\"NYR\",{\"className\":\"flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"NYR\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Nyrada Inc.\"}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.80\"]}],[\"$\",\"span\",null,{\"className\":\"text-sm font-semibold text-emerald-400\",\"children\":[\"+\",\"644.2\",\"%\"]}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-2xl border border-white/10 bg-ink-900/80 p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Worst Performers\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3\",\"children\":[[\"$\",\"div\",\"ENL\",{\"className\":\"flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"ENL\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Enlitic Inc.\"}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"span\",null,{\"className\":\"text-sm font-semibold text-red-400\",\"children\":[\"\",\"-87.0\",\"%\"]}]]}]]}],[\"$\",\"div\",\"UBI\",{\"className\":\"flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"UBI\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Universal Biosensors Inc.\"}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"span\",null,{\"className\":\"text-sm font-semibold text-red-400\",\"children\":[\"\",\"-79.7\",\"%\"]}]]}]]}],[\"$\",\"div\",\"BOT\",{\"className\":\"flex items-center justify-between rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"BOT\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Botanix Pharmaceuticals Ltd\"}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.11\"]}],[\"$\",\"span\",null,{\"className\":\"text-sm font-semibold text-red-400\",\"children\":[\"\",\"-75.8\",\"%\"]}]]}]]}]]}]]}]]}],[\"$\",\"section\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-end justify-between\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-2xl font-semibold\",\"children\":[\"All \",\"health care\",\" Coverage\"]}],[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-400\",\"children\":[\"Showing \",20,\" of \",166,\" stocks\"]}]]}],[\"$\",\"div\",null,{\"className\":\"grid gap-6 md:grid-cols-2\",\"children\":[[\"$\",\"$L6\",null,{\"href\":\"/asx/4DX\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"4DX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"4Dmedical Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.85\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"1325.9\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"4Dmedical Limited specializes in developing and commercializing state-of-the-art respiratory imaging technology, notably its XV Lung Ventilation Analysis Software (XV LVAS). This non-invasive technology provides quantitative and visual assessments of regional lung function, aiming to improve the diagnosis and management of various respiratory conditions. The company primarily operates in Australia and is aggressively expanding its presence in the large US healthcare market.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$2.0B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/LDX\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"LDX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Lumos Diagnostics Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.26\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"983.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Lumos Diagnostics Holdings Limited (ASX: LDX) is an Australian-based company developing and commercialising rapid, point-of-care (POC) diagnostic tests for infectious diseases. Their flagship product, FebriDx, aims to differentiate bacterial from viral infections within minutes, assisting clinicians in reducing unnecessary antibiotic prescriptions. Lumos operates globally with R\u0026D and manufacturing facilities in the US, targeting healthcare markets across North America, Europe, and Australia.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$218M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NYR\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NYR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Nyrada Inc.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.80\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"644.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Nyrada Inc. is an Australian-based biotechnology company focused on the development of novel neuroprotectants and cardiovascular therapeutics. The company's lead programs target significant medical needs such as traumatic brain injury, stroke, and certain cardiovascular diseases, with drug candidates in pre-clinical and early clinical development phases. Nyrada operates primarily in the research and development sector, aiming to develop first-in-class treatments.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$198M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/DVL\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"DVL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Dorsavi Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"483.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Dorsavi Ltd (ASX: DVL) is an Australian-based company that develops wearable sensor technology and software solutions for analyzing human movement. Their proprietary technology provides objective data for injury prevention, performance enhancement, and clinical rehabilitation across elite sports, occupational health, and healthcare sectors, operating globally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$39M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/SPL\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"SPL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Starpharma Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.49\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"421.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Starpharma Holdings Limited (SPL) is an Australian biotech company specializing in pharmaceuticals and life sciences. Headquartered in Melbourne, SPL operates globally, focusing on drug delivery technologies, with its lead product being Dendrimers, particularly the proprietary DuraGel technology for enhancing drug efficacy and safety. Key products include clinical-stage oncology and infectious disease treatments.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$174M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AYA\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AYA\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Artrya Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"3.56\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"374.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Artrya Limited is an Australian medical technology company that develops and commercializes AI-powered software for the diagnosis of coronary artery disease. Its flagship product, Salix, analyzes cardiac CT scans to identify stenosis and vulnerable plaque, aiming to improve diagnostic accuracy and prevent heart attacks. The company targets cardiologists, radiologists, and hospitals globally, with key regulatory approvals in Australia, Europe, and the USA.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$550M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/1AI\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AI\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Algorae Pharmaceuticals Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"320.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere's disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$37M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/NSB\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"NSB\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Neuroscientific Biopharmaceuticals Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.13\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"251.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Neuroscientific Biopharmaceuticals Ltd (NSB) is an Australian clinical-stage pharmaceutical company focused on developing novel peptide-based drugs for neurological and neurodegenerative disorders. Their lead drug candidate, EmtinB, targets conditions such as Alzheimer's disease, Multiple Sclerosis, and glaucoma, aiming to address significant unmet medical needs. The company is advancing its proprietary therapeutic compounds through various stages of preclinical and clinical development.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$43M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ICR\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ICR\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Intelicare Holdings Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.02\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"233.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Intelicare Holdings Limited (ASX: ICR) is an Australian technology company specializing in AI-powered assistive living solutions for the aged care and disability support sectors. Its flagship InteliCare platform uses sensors and artificial intelligence to monitor the well-being of individuals remotely, providing insights to carers and family members without invasive surveillance. The company primarily operates within the Australian market, aiming to improve independent living outcomes.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$14M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RHY\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RHY\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Rhythm Biosciences Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.24\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"206.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Rhythm Biosciences Limited (ASX: RHY) is an Australian medical diagnostics company focused on developing and commercialising its lead product, ColoSTAT, a simple blood test for the early detection of colorectal cancer. The company aims to provide a more accessible and non-invasive screening solution globally, primarily targeting markets in Australia, Europe, and the USA.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$74M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/BB1\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"BB1\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Blinklab Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"167.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Blinklab Limited (ASX: BB1) is a Australian health tech company, operating in the health care equipment and services sector. Specific to the Australian market, it develops innovative, non-invasive diagnostic devices for early detection of ophthalmological conditions, leveraging AI-driven analysis. Key product is 'EyeSightAI', targeting the Australian healthcare system and private clinics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$128M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/ILA\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"ILA\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Island Pharmaceuticals Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.41\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"148.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Island Pharmaceuticals Limited (ASX: ILA) is an early-stage Australian biotechnology company focused on the research, development, and commercialization of innovative therapeutic solutions in the pharmaceuticals and biotechnology sector. Primarily operating in Australia, with potential for global clinical trials, ILA is currently pre-revenue, concentrating on advancing its lead compound through clinical phases, targeting specific unmet medical needs. Key products/services include its proprietary drug candidate for [undisclosed target disease/condition, assuming specificity not publicly available, thus a placeholder].\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$112M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AT1\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AT1\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Atomo Diagnostics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"141.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Atomo Diagnostics Limited (ASX: AT1) is an Australian medical device company specialising in the design, manufacture, and commercialisation of user-friendly rapid diagnostic test (RDT) devices. Its patented AtomoRapid platform simplifies blood-based point-of-care and self-test applications, aiming to improve testing accuracy and accessibility for various infectious diseases globally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$33M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/RAC\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"RAC\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Racura Oncology Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"2.40\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"125.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Ratura Oncology Ltd (ASX: RAC) is an Australian-listed biotechnology company focused on the discovery, development, and commercialization of novel therapeutic candidates for the treatment of various cancers. Operating primarily in the preclinical and clinical trial phases, the company aims to address unmet medical needs within oncology by advancing its pipeline of drug candidates.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$445M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AHX\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AHX\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Apiam Animal Health Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.88\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"124.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Apiam Animal Health Limited is a leading provider of veterinary services, operating a network of clinics predominantly across regional and rural Australia. The company offers a comprehensive range of veterinary care for companion animals, equine, and livestock, along with related products and services.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$-1\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/TRI\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"TRI\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Trivarx Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"122.2\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Trivarx Ltd is an Australian medical technology company developing its proprietary 'Cardi-Dx' point-of-care diagnostic platform. The device is designed for the rapid detection of key cardiac biomarkers from a single drop of blood, targeting the early and accurate diagnosis of acute cardiac events in emergency departments and clinics. The company is currently advancing the Cardi-Dx system through clinical trials and regulatory approval pathways in Australia and Europe.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$29M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/HMD\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"HMD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Heramed Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.04\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"121.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Heramed Limited (ASX: HMD) is an Australian-Israeli digital health company focused on remote pregnancy monitoring solutions. Its flagship product, HeraBEAT, is a medical-grade, CE-marked, and TGA-approved device enabling expectant mothers to monitor vital signs and fetal heart rate from home. The company operates globally by partnering with healthcare providers and health systems to integrate its technology into patient care pathways.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$45M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CYP\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CYP\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Cynata Therapeutics Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.39\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"110.8\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Cynata Therapeutics Limited (ASX: CYP) is an Australian biotechnology company focused on developing innovative cellular therapies for serious diseases using its proprietary Cell Control Technology. Operating primarily in the Australian market with research collaborations globally, its key product in development is rCTRM, a mesenchymal stromal cell therapy for acute respiratory distress syndrome (ARDS) and other inflammatory conditions.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$91M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/CC5\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CC5\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Clever Culture Systems Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.03\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"107.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Clever Culture Systems Limited (CC5) is an Australian healthcare equipment and services company developing innovative cell culture solutions for the biotechnology and pharmaceutical industries. Operating primarily in Australia, with potential expansion to APAC regions, its key product is the Clever Culture SystemTM, designed to enhance cell growth and efficiency in research and production settings.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$65M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L6\",null,{\"href\":\"/asx/AVE\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"AVE\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Avecho Biotechnology Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-emerald-400\",\"children\":[\"100.0\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Avecho Biotechnology Limited (ASX: AVE) operates in Australia, specializing in the development of innovative therapeutic products for unmet medical needs. Focused on proprietary formulations and delivery technologies for existing drugs, improving efficacy and patient outcomes. Key product pipeline: Novel formulations for pain management and neurology.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$35M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"text-center text-sm text-slate-500\",\"children\":[\"+\",146,\" more \",\"health care\",\" stocks available. Use the\",\" \",[\"$\",\"a\",null,{\"href\":\"/screener\",\"className\":\"text-blue-400 hover:underline\",\"children\":\"Screener\"}],\" \",\"to filter and explore the full list.\"]}]]}]]}]],null],null]},[\"$\",\"$L7\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"sectors\",\"children\",\"$8\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L9\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[\"$\",\"$L7\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"sectors\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L9\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"__variable_6d343d __variable_49a339\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/logo.svg\",\"type\":\"image/svg+xml\"}]}],[\"$\",\"body\",null,{\"className\":\"min-h-screen bg-ink-900 text-slate-100\",\"children\":[\"$\",\"div\",null,{\"className\":\"min-h-screen\",\"children\":[[\"$\",\"header\",null,{\"className\":\"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"$L6\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"$La\",null,{\"src\":\"/logo.svg\",\"alt\":\"ASX Desk\",\"width\":140,\"height\":40,\"className\":\"h-10 w-auto\",\"priority\":true}],[\"$\",\"span\",null,{\"className\":\"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline\",\"children\":\"Research Terminal\"}]]}],[\"$\",\"nav\",null,{\"className\":\"hidden items-center gap-6 text-sm text-slate-300 md:flex\",\"children\":[[\"$\",\"$L6\",\"/\",{\"href\":\"/\",\"className\":\"transition hover:text-white\",\"children\":\"Home\"}],[\"$\",\"$L6\",\"/screener\",{\"href\":\"/screener\",\"className\":\"transition hover:text-white\",\"children\":\"Screener\"}],[\"$\",\"$L6\",\"/sectors\",{\"href\":\"/sectors\",\"className\":\"transition hover:text-white\",\"children\":\"Sectors\"}],[\"$\",\"$L6\",\"/news\",{\"href\":\"/news\",\"className\":\"transition hover:text-white\",\"children\":\"News\"}],[\"$\",\"$L6\",\"/ipos\",{\"href\":\"/ipos\",\"className\":\"transition hover:text-white\",\"children\":\"IPOs\"}],[\"$\",\"$L6\",\"/compare\",{\"href\":\"/compare\",\"className\":\"transition hover:text-white\",\"children\":\"Compare\"}],[\"$\",\"$L6\",\"/about\",{\"href\":\"/about\",\"className\":\"transition hover:text-white\",\"children\":\"About\"}]]}],[\"$\",\"div\",null,{\"className\":\"hidden items-center gap-3 md:flex\",\"children\":[[\"$\",\"$Lb\",null,{}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20\",\"children\":\"Premium Research\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400\",\"children\":\"Open Account\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-1\",\"children\":[\"$\",\"$Lb\",null,{}]}],[\"$\",\"$L6\",null,{\"href\":\"/screener\",\"className\":\"shrink-0 text-xs text-blue-300\",\"children\":\"Screener\"}]]}]]}],[\"$\",\"main\",null,{\"className\":\"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8\",\"children\":[\"$\",\"$L7\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L9\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"div\",null,{\"className\":\"flex min-h-[60vh] flex-col items-center justify-center text-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"404\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":\"Page not found\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"We couldn't locate that ASX page. Try searching a ticker or visit the homepage.\"}],[\"$\",\"$L6\",null,{\"href\":\"/\",\"className\":\"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Back to Home\"}]]}],\"notFoundStyles\":[],\"styles\":null}]}],[\"$\",\"footer\",null,{\"className\":\"border-t border-white/10 bg-ink-800/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"ASX Desk\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-3\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300\",\"children\":\"Download Media Kit\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-6 text-sm text-slate-400\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Platform\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/screener\",\"className\":\"hover:text-white\",\"children\":\"Screener\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/news\",\"className\":\"hover:text-white\",\"children\":\"News \u0026 Commentary\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/about\",\"className\":\"hover:text-white\",\"children\":\"About\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Sectors\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/materials\",\"className\":\"hover:text-white\",\"children\":\"Materials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/financials\",\"className\":\"hover:text-white\",\"children\":\"Financials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/health care\",\"className\":\"hover:text-white\",\"children\":\"Health Care\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/information technology\",\"className\":\"hover:text-white\",\"children\":\"Information Tech\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L6\",null,{\"href\":\"/sectors/energy\",\"className\":\"hover:text-white\",\"children\":\"Energy\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold\",\"children\":\"Weekly Alpha Briefing\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex flex-col gap-3 sm:flex-row\",\"children\":[[\"$\",\"input\",null,{\"type\":\"email\",\"placeholder\":\"you@example.com\",\"className\":\"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Subscribe\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"By subscribing you agree to receive marketing updates. Unsubscribe anytime.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-white/10 py-6 text-center text-xs text-slate-500\",\"children\":[\"$\",\"p\",null,{\"children\":\"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.\"}]}]]}]]}]}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$Lc\"],\"globalErrorComponent\":\"$d\",\"missingSlots\":\"$We\"}]]\n"])</script><script>self.__next_f.push([1,"c:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"health care sector stocks on the ASX | trends \u0026 top performers | ASX Desk\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Explore ASX health care stocks, sector trends, and leading performers with AI-generated insights.\"}],[\"$\",\"link\",\"4\",{\"rel\":\"canonical\",\"href\":\"https://asxdesk.com/sectors/health%20care/\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:title\",\"content\":\"health care sector stocks on the ASX | trends \u0026 top performers\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:description\",\"content\":\"Explore ASX health care stocks, sector trends, and leading performers with AI-generated insights.\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:url\",\"content\":\"https://asxdesk.com/sectors/health%20care/\"}],[\"$\",\"meta\",\"8\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:title\",\"content\":\"ASX Desk\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:description\",\"content\":\"Australia's AI-powered ASX stock research platform delivering instant analysis, sector insights, and SEO-optimized company profiles.\"}],[\"$\",\"meta\",\"11\",{\"name\":\"next-size-adjust\"}]]\n5:null\n"])</script></body></html>